NRx Pharmaceuticals, Inc. (NRXP)

NASDAQ: NRXP · USD

$2.69

+0.00 (0.0%)· Recorded snapshot

Market cap	116.4M
Revenue (ttm)	3.4M
Net income (ttm)	-23.5M
EPS (ttm)	-$0.78
Shares out	43.3M
Volume	768,106
Beta	2.07

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.4M
Net income (ttm): -23.5M
EPS (ttm): -$0.78
Market cap: 116.4M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROEn/a

P25 n/aP50 n/aP75 n/a

ROICn/a

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All NRXP indicators

Market & fundamental data

Available fields

187

Groups with data

Currency

USD

Showing 187 of 187 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001719406
Company name	NRx Pharmaceuticals, Inc.
Country	United States
Country code	US
CUSIP number	629444209
Earnings date	2026-11-16
Earnings time	bmo
Employees	29
Enterprise value	$90.5M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US6294442099
Last 10-K release date	2026-03-23
Last earnings date	2026-08-17
Last refreshed	2026-10-28
Last stock split date	2024-04-02
Last stock split type	Reverse
Market cap	$116.4M
Market cap category	Micro-Cap
Next earnings date	2026-11-16
Options	Yes
Price	$2.69
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	NRXP
U.S. state	Delaware
Website	https://www.nrxpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-28.83%
EV/Sales	26.74x
FCF / EV yield	-22.78%
FCF yield	-17.73%
Forward EV/Sales	2.48x
Forward P/S	3.18x
P/S ratio	34.35x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	46.64%
Operating margin	-588.21%
Pretax margin	-691.81%
Profit per employee	$-809,655
Revenue per employee	$117,034
ROA	-63.99%
ROA (5Y)	-175.22%
ROCE	-6,980.42%
SBC / revenue	54.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	4
Net income growth quarters	3
Net income growth years	0
Revenue growth (QoQ)	3.09%
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-897,000
Depreciation and amortization	$202,000
EBIT	$-20M
EBITDA	$-19.8M
EPS	$-0.78
FCF per share	$-0.48
Financing cash flow	$47.3M
Free cash flow	$-20.7M
Free cash flow minus SBC	$-22.5M
Gross profit	$1.6M
Investing cash flow	$-3.7M
Net borrowing	$33,000
Net cash flow	$23.8M
Net income	$-23.5M
Operating cash flow minus SBC	$-21.6M
Operating income	$-20M
Revenue	$3.4M
Stock-based compensation	$1.9M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-13.93
Book value per share	$-0.00
Goodwill	$1.8M
Interest coverage	-17.5
Long-term assets	$5M
Long-term liabilities	$456,000
Net cash (debt)	$25.9M
Net cash / market cap	22.17%
Piotroski F-Score	2
Property, plant and equipment	$1.8M
Shareholders' equity	$-170,000
Tangible book value	$-2.8M
Tangible book value per share	$-0.06
Total assets	$34.2M
Total cash	$26.7M
Total debt	$834,000
Total liabilities	$34.3M
WACC	16.31%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.17
Current assets	$29.2M
Current liabilities	$33.9M
Current ratio	0.86
Net working capital	$-31M
Quick ratio	0.79
Working capital	$-4.7M
Working capital turnover	-0.17

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-110.42%
Dividend yield	0%
Shareholder yield	-110.42%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$3.30
1D price change	0%
1M price change	-11.52%
1M total return	-11.52%
1W price change	1.15%
1W total return	1.15%
1Y price change	-15.61%
1Y return CAGR	-15.61%
1Y total return	-15.61%
20-day SMA	$2.72
200-day SMA	$2.96
3M price change	-27%
3M total return	-27%
3Y price change	-13.26%
3Y return CAGR	-4.63%
3Y total return	-13.26%
50-day SMA	$3.10
50-day SMA vs 200-day SMA	50over200
52-week high	$5.06
52-week high date	2026-06-02
52-week low	$1.62
52-week low date	2026-03-09
5Y price change	-97.43%
5Y return CAGR	-51.92%
5Y total return	-97.43%
6M price change	-12.54%
6M total return	-12.54%
All-time high	$769.90
All-time high date	2020-12-22
All-time low	$1.10
All-time low date	2024-10-16
Average true range (ATR)	$0.17
Average volume	731.9K
Beta (1Y)	2.1
Beta (2Y)	0.84
Beta (5Y)	2.07
Change from 52-week high	-46.79%
Change from 52-week low	66.05%
Change from all-time high	-99.66%
Change from all-time low	140.91%
Change from open	-1.47%
Day's gap	1.49%
Dollar volume	$2.1M
High price	$2.74
Low price	$2.64
Monthly RSI	42.24
Open price	$2.73
Position in 52-week range	50%
Premarket change	1.1%
Premarket close	$2.69
Premarket price	$2.72
Premarket volume	3.3K
Previous close	$2.69
Price vs 150-day SMA	-19.72%
Price vs 20-day SMA	-2.43%
Price vs 200-day SMA	-10.59%
Price vs 50-day SMA	-14.43%
Relative volume	1.05
RSI	42.3
Sharpe ratio	0.16
Sharpe ratio (3Y)	0.47
Sharpe ratio (5Y)	-0.13
Sortino ratio	0.35
Sortino ratio (3Y)	0.85
Sortino ratio (5Y)	-0.14
Volume	768.1K
Weekly RSI	42.25
YTD price change	-2.21%
YTD total return	-2.21%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	37.4M
Float percentage	86.42%
Shares change (QoQ)	16.47%
Shares change (YoY)	110.42%
Shares held by insiders	4.12%
Shares held by institutions	21.87%
Shares outstanding	43.3M
Short % of float	26.61%
Short % of shares	23%
Short ratio	15.1 days

Deeper analysis on NRXP

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this NRXP report

Is a complete NRXP research report available?

No complete published report is available for NRx Pharmaceuticals, Inc. (NRXP) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

NRx Pharmaceuticals, Inc. (NRXP)

Price

Financial snapshot

Fair-value bridge

Latest news · NRXP

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All NRXP indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on NRXP

Frequently asked questions